secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2022-04-25T23:59:59+00:00
Accession:  0001193125-22-116331
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead forms JV with Vivo Capital for Greater China; licenses four RNAi cardiometabolic drugs
--------------------------------------------------------------------------------

- Vivo Capital provided $60M initial funding to Visirna Therapeutics, JV in which Arrowhead holds majority stake.
- Visirna gets exclusive rights to develop and commercialize four investigational RNAi therapeutics in Greater China.
- Arrowhead eligible to receive royalties on net commercial sales in the licensed territory.
- Vivo Capital's Hongbo Lu and Gaurav Aggarwal to join Visirna board; Arrowhead also appoints board members.
- Visirna to be headquartered in Shanghai; recruitment of management and staff underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000119312522116331/0001193125-22-116331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000119312522116331/d203945d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-116331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer